Equities Analysts Offer Predictions for ABEO Q1 Earnings

Abeona Therapeutics Inc (NASDAQ:ABEO) – Investment analysts at HC Wainwright issued their Q1 2026 earnings estimates for shares of Abeona Therapeutics in a research report issued on Monday, March 24th. HC Wainwright analyst R. Selvaraju anticipates that the biopharmaceutical company will post earnings of ($0.10) per share for the quarter. HC Wainwright has a “Buy” rating and a $15.00 price objective on the stock. The consensus estimate for Abeona Therapeutics’ current full-year earnings is ($1.16) per share. HC Wainwright also issued estimates for Abeona Therapeutics’ Q2 2026 earnings at ($0.06) EPS, Q3 2026 earnings at ($0.01) EPS, Q4 2026 earnings at $0.05 EPS and FY2026 earnings at ($0.12) EPS.

Several other analysts have also recently issued reports on the stock. Oppenheimer started coverage on shares of Abeona Therapeutics in a report on Wednesday, March 5th. They issued an “outperform” rating and a $16.00 price target on the stock. StockNews.com raised shares of Abeona Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $17.50.

Abeona Therapeutics Stock Performance

Shares of ABEO opened at $4.99 on Tuesday. The firm has a market cap of $216.92 million, a price-to-earnings ratio of -1.86 and a beta of 1.79. The company has a quick ratio of 6.12, a current ratio of 6.12 and a debt-to-equity ratio of 0.31. The business’s 50 day moving average is $5.43 and its two-hundred day moving average is $5.82. Abeona Therapeutics has a 52-week low of $3.05 and a 52-week high of $8.45.

Abeona Therapeutics (NASDAQ:ABEO) last issued its quarterly earnings results on Thursday, March 20th. The biopharmaceutical company reported ($0.24) EPS for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.19.

Institutional Investors Weigh In On Abeona Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the company. Charles Schwab Investment Management Inc. acquired a new position in Abeona Therapeutics in the third quarter worth $151,000. Citigroup Inc. lifted its position in shares of Abeona Therapeutics by 10.1% in the 3rd quarter. Citigroup Inc. now owns 616,668 shares of the biopharmaceutical company’s stock worth $3,897,000 after buying an additional 56,332 shares during the last quarter. Western Standard LLC boosted its holdings in shares of Abeona Therapeutics by 7.0% in the 3rd quarter. Western Standard LLC now owns 1,698,097 shares of the biopharmaceutical company’s stock valued at $10,732,000 after buying an additional 110,998 shares during the period. Jane Street Group LLC bought a new stake in shares of Abeona Therapeutics during the 3rd quarter valued at about $84,000. Finally, XTX Topco Ltd acquired a new stake in Abeona Therapeutics during the third quarter worth about $160,000. 80.56% of the stock is owned by institutional investors and hedge funds.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.